Table 3.

Select (with a potential immunologic etiology) treatment-related adverse events in ≥5% of patients

	Nivolumab plus ipilimumab (N = 754)
	Any grade, n (%)	Grade 3–4, n (%)
Skin	497 (66)	45 (6)
Pruritus	193 (26)	4 (1)
Maculopapular rash	182 (24)	27 (4)
Rash	125 (17)	6 (1)
Generalized pruritus	84 (11)	3 (<1)
Pruritic rash	58 (8)	0
Vitiligo	38 (5)	1 (<1)
Gastrointestinal	331 (44)	120 (16)
Diarrhea	303 (40)	70 (9)
Colitis	80 (11)	58 (8)
Hepatic	266 (35)	118 (16)
Increased aspartate aminotransferase	186 (25)	55 (7)
Increased alanine aminotransferase	181 (24)	69 (9)
Increased blood alkaline phosphatase	45 (6)	3 (<1)
Autoimmune hepatitis	42 (6)	30 (4)
Endocrine	223 (30)	22 (3)
Hypothyroidism	96 (13)	2 (<1)
Hyperthyroidism	58 (8)	4 (1)
Hypophysitis	44 (6)	7 (1)
Pulmonary	50 (7)	11 (1)
Pneumonitis	49 (6)	11 (1)
Renal	38 (5)	13 (2)